Lakefront Biotherapeutics ADR (LKFT)
NASDAQ: LKFTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 30.00 0.00%
LKFT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.96B
- P/E (TTM)
- 2.85
- EPS (TTM)
- $10.52
- Dividend yield
- None
- 52-week range
- 25.68 – 36.24
- Day range
- 29.00 – 30.05
- Volume / Avg
- 362.25K / 263.15K
- Beta
- —
- Shares outstanding
- 65.48M
- Next earnings
- Nov 11, 2026
52-week range
LKFT stock today
On Oct 7, LKFT ended the session at $30.00, adding $0.68 (2.32%), versus the S&P 500's 0.22% decline. Shares are 17.2% below their 52-week high of $36.24 and 16.8% above the 52-week low of $25.68, in the middle of the past year's range. LKFT is down 8.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 14.1%.
Lakefront Biotherapeutics trades at 2.9x its trailing twelve-month earnings per share of $10.52. Lakefront Biotherapeutics's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Lakefront Biotherapeutics
Company profileLakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Henry O. Gosebruch
- Headquarters
- Mechelen
- Employees
- 196
- IPO year
- 2015
- Website
- lakefrontbio.com
Analyst forecast
ForecastConsensus (6 analysts)
hold
Avg. price target
$30.18+0.60%
- Strong buy 1
- Buy 1
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
Lakefront Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MLYSMineralys Therapeutics Inc. | 22.09 | +0.64% | $1.95B | vs LKFT |
| ZYMEZymeworks Inc. | 26.53 | +3.43% | $1.90B | vs LKFT |
| GPCRStructure Therapeutics Inc. ADR | 26.68 | -2.88% | $1.90B | vs LKFT |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs LKFT |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs LKFT |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs LKFT |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs LKFT |
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs LKFT |
Indexes, lists and sector
Lakefront Biotherapeutics stock FAQ
What is Lakefront Biotherapeutics's stock price today?
LKFT last traded at $30.00 as of Oct 7, 4:00 PM EDT, up 2.32% on the day. Prices are delayed at least 15 minutes.
When is Lakefront Biotherapeutics's next earnings date?
Lakefront Biotherapeutics is expected to report earnings on Wednesday, November 11, 2026.
What is LKFT's P/E ratio?
LKFT trades at a trailing P/E ratio of 2.85.
Who is Lakefront Biotherapeutics's CEO?
Mr. Henry O. Gosebruch is the chief executive officer of Lakefront Biotherapeutics ADR, which has about 196 employees.
What is the LKFT 52-week high?
The 52-week high for LKFT is $36.24 and the 52-week low is $25.68. The stock is currently 17.2% below its high.